The Federal Trade Commission is likely to pursue more aggressive review of pharmaceutical matters now that Alvaro Bedoya has joined the commission, giving it a Democratic majority.
Until his swearing in on 16 May, the Commission had been functioning with two Democrat and two Republican members after...